Caliper Technologies Corp
This article was originally published in The Gray Sheet
Executive Summary
Initial public offering of 4.5 mil. shares at $16 each grosses $72 mil. Larger than the previously anticipated 3.6 mil. shares at $13-15 each, the IPO will help fund scale-up of manufacturing operations for initial LabChip "lab-on-a-chip" technologies and further R&D activities (1"The Gray Sheet" Dec. 6, p. 16). The Mountain View, California firm's stock is trading under the symbol "CALP," and not "CLPR" as expected earlier. Credit Suisse First Boston, CIBC World Markets Corp. and Hambrecht & Quist LLC were underwriters for the offering
You may also be interested in...
Caliper's $46 Mil. IPO To Fund LabChip Manufacturing Scale-Up, R&D
Development of "lab-on-a-chip" technologies used in high-throughput nucleic acid analysis for diagnostics applications is one of several development projects that would benefit from Caliper Technologies' $46 mil. initial public offering.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.